 Nes-Ziona, Israel, March 03, 2020 GLOBE NEWSWIRE -- Enlivex Therapeutics Ltd. ENLV, a clinical-stage immunotherapy company, today confirmed the public statements made by the Head of Israel Economic and Commercial Mission to South Korea, regarding a proposal submitted by Enlivex and the Head of Israel Economic and Commercial Mission to South Korea to South Korean authorities with respect to the potential use of AllocetraTM as treatment of patients with Coronavirus COVID-19 patients who are hospitalized in intensive care units and suffering from organ dysfunctions or failures. AllocetraTM is an experimental therapy being investigated for treatment of patients with organ failure associated with sepsis, a syndrome whose lethal pathophysiology hyper stimulation of the immune response and cytokine storm followed by organ failure that may be similar to that of the coronavirus COVID-19 associated with the newly recognized virus SARS-CoV-2. 